Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and
cabozantinib to assess overall response rate (ORR), progression free survival at 6 months
(PFS6), and overall survival (OS) in patients with metastatic urothelial carcinoma (UC)
ineligible for cisplatin.